CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial

Publication Date

2026

Content Type

article

PubMed ID:

42120728

Additional Authors:

Additional Authors and Institutional Affiliations

This document is currently not available here.

Share

COinS